Citations

Clear

477 citation(s) found for "Wallace, AM".

Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐Analysis
Putman, Michael , Chock, Yu Pei Eugenia, Tam, Herman , Kim, Alfred H.J. , Sattui, Sebastian E. , Berenbaum, Françis , Korsten, Peter , Sánchez-Álvarez, Catalina , Sparks, Jeffrey A. , Coates, Laura C. , Palmerlee, Candace A, Peirce, Andrea, Jayatilleke, Arundathi , Johnson, Sindhu R., Kilian, Adam , Grainger, Rebecca , Wallace, Zachary S. , Alliance, the COVID‐19 Global Rheumatology, Korsten, Peter , Sanchez-Alvarez, Catalina , Sparks, Jeffrey A , Coates, Laura C , Liew, Jean , Grainger, Rebecca , Duarte-García, Alí , Jayatilleke, Arundathi , Kim, Alfred H J , Sattui, Sebastian E , Berenbaum, Francis , Danila, Maria I. , Johnson, Sindhu R. , Liew, Jean W. , Prokop, Larry J. , Murad, M. Hassan , Duarte‐García, Alí , Alliance, the COVID‐19 Global Rheumatology

Mayo Clinic

Arthritis & Rheumatology | August 2, 2020 | Volume: 73 | Issue: 1 | Pages: 36-47

10.1002/art.41469 | PMID 32741139 Get It

ObjectiveAntirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID‐19) and its complications. We conducted a systematic review and meta‐analysis to describe the current evidence.MethodsA search of published and preprint databases in all languages was performed. Included studies described ≥1 relevant clinical outcome for ≥5 patients who were infected with severe acute respiratory syndrome coronavirus 2 and were treated with antirheumatic disease therapy between January 1, 2019 and May 29, 2020. Pairs of reviewers screened articles, extracted data, and assessed risk of bias. A meta‐analysis of effect sizes using random‐effects models was performed when possible.ResultsThe search identified 3,935 articles, of which 45 were included (4 randomized controlled trials, 29 cohort studies, and 12 case series). All studies evaluated hospitalized patients, and 29 of the 45 studies had been published in a peer‐reviewed journal. In a meta‐analysis of 3 cohort studies with a low risk of bias, hydroxychloroquine use was not significantly associated with mortality (pooled hazard ratio [HR] 1.41 [95% confidence interval (95% CI) 0.83, 2.42]). In a meta‐analysis of 2 cohort studies with some concerns/higher risk of bias, anakinra use was associated with lower mortality (pooled HR 0.25 [95% CI 0.12, 0.52]). Evidence was inconclusive with regard to other antirheumatic disease therapies, and the majority of other studies had a high risk of bias.ConclusionIn this systematic review and meta‐analysis, hydroxychloroquine use was not associated with benefit or harm regarding COVID‐19 mortality. The evidence supporting the effect of other antirheumatic disease therapies in COVID‐19 is currently inconclusive.
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
Yee, Douglas , Symmans, W. Fraser , Albain, Kathy S. , Chen, Yunn-Yi, Krings, Gregor , Wei, Shi , Harada, Shuko , Datnow, Brian, Fadare, Oluwole , Klein, Molly, Chen, Beiyun, Adamson, Kathi, Sams, Sharon B. , Mhawech‐Fauceglia, Paulette , Magliocco, Anthony M., Feldman, Mike, Rendi, Mara H. , Sattar, Husain, Zeck, Jay , Ocal, Idris Tolgay, Tawfik, Ossama , LeBeau, Lauren, Sahoo, Sunati , Vinh, Tuyethoa N., Chien, A. Jo , Forero‐Torres, Andres , Stringer-Reasor, Erica , Ellis, Erin D. , Lu, Janice , Lang, Julie E. , Clark, Amy S. , Nanda, Rita , Northfelt, Donald W. , Khan, Qamar J. , Viscusi, Rebecca K., Euhus, David , Edmiston, Kirsten K., Kemmer, Kathleen, Park, John W., Liu, Minetta C. , Olopade, Olufunmilayo I. , Leyland‐Jones, Brian , Tripathy, Debasish , Moulder, Stacy L. , Schwab, Richard B. , Lo, Shelly S. , Beckwith, Heather , Haugen, Patricia, Veer, Laura J. van’t , Perlmutter, Jane , Melisko, Michelle , Wilson, Amy , Peterson, Garry , Buxton, Meredith , Paoloni, Melissa, Clennell, Julia L. , Hirst, Gillian L. , Singhrao, Ruby , Steeg, Katherine, Matthews, Jeffrey B. , Asare, Smita , Sanil, Ashish, Esserman, Laura J. , Berry, Donald A. , Tripathy, Debu , Ocal, Idris T, Olopade, Olufunmilayo I , Symmans, W Fraser , Esserman, Laura J , Hirst, Gillian L , Yee, Douglas , DeMichele, Angela , Yau, Christina , Isaacs, Claudine , Chen, Yunn‐Yi , Krings, Gregor, Pambuccian, Stefan E. , Wallace, Anne M. , Pusztai, Lajos , Boughey, Judy C. , Elias, Anthony , Han, Hyo S , Chui, Stephen Y., Rugo, Hope S. , Helsten, Teresa L. , Hylton, Nola M. , Asare, Adam L. , Matthews, Jeffrey B., Berry, Scott

Mayo Clinic

JAMA Oncology | July 23, 2020 | Volume: 6 | Issue: 9 | Pages: 1355

10.1001/jamaoncol.2020.2535 | PMID 32701140 Get It

Multicenter study on the diagnostic performance of multiframe volumetric laser endomicroscopy targets for Barrett’s esophagus neoplasia with histopathology correlation
Struyvenberg, Maarten R., Groof, A J de , Kahn, Allon , Weusten, Bas L. , Fleischer, David E., Ganguly, Eric K. , Konda, Vani J. , Lightdale, Charles J. , Sethi, Amrita , Smith, Michael S. , Wallace, Michael B. , Wolfsen, Herbert C. , Tearney, Guillermo J. , Leggett, Cadman L. , Bergman, Jacques , Curvers, Wouter L., Wallace, Michael B , Leggett, Cadman L , Kahn, Allon , Pleskow, Douglas K. , Trindade, Arvind J. , Meijer, Sybren L.

Mayo Clinic

Diseases of the Esophagus | July 1, 2020 | Volume: 33 | Issue: 12 | Pages: No page available

10.1093/dote/doaa062 | PMID 32607539 Get It

AbstractVolumetric laser endomicroscopy (VLE) has been shown to improve detection of early neoplasia in Barrett’s esophagus (BE). However, diagnostic performance using histopathology-correlated VLE regions of interest (ROIs) has not been adequately studied. We evaluated the diagnostic accuracy of VLE assessors for identification of early BE neoplasia in histopathology-correlated VLE ROIs. In total, 191 ROIs (120 nondysplastic and 71 neoplastic) from 50 BE patients were evaluated in a random order using a web-based module. All ROIs contained histopathology correlations enabled by VLE laser marking. Assessors were blinded to endoscopic BE images and histology. ROIs were first scored as nondysplastic or neoplastic. Level of confidence was assigned to the predicted diagnosis. Outcome measures were: (i) diagnostic performance of VLE assessors for identification of BE neoplasia in all VLE ROIs, defined as accuracy, sensitivity, and specificity; (ii) diagnostic performance of VLE assessors for only high level of confidence predictions; and (iii) interobserver agreement. Accuracy, sensitivity, and specificity for BE neoplasia identification were 79% (confidence interval [CI], 75–83), 75% (CI, 71–79), and 81% (CI, 76–86), respectively. When neoplasia was identified with a high level of confidence, accuracy, sensitivity, and specificity were 88%, 83%, and 90%, respectively. The overall strength of interobserver agreement was fair (k = 0.29). VLE assessors can identify BE neoplasia with reasonable diagnostic accuracy in histopathology-correlated VLE ROIs, and accuracy is enhanced when BE neoplasia is identified with high level of confidence. Future work should focus on renewed VLE image reviewing criteria and real-time automatic assessment of VLE scans.
Expert assessment on volumetric laser endomicroscopy full scans in Barrett’s esophagus patients with or without high grade dysplasia or early cancer
Struyvenberg, Maarten R., Fleischer, David E., Swager, Anne-Fré, Bouma, Brett E. , Ganguly, Eric K. , Konda, Vani J. , Lightdale, Charles J. , Pleskow, Douglas K. , Sethi, Amrita , Smith, Michael S. , Wallace, Michael B. , Wang, Kenneth T. , Wolfsen, Herbert C. , Tearney, Guillermo J. , Curvers, Wouter L., Leggett, Cadman L. , Bergman, Jacques , Kahn, Allon , Fleischer, David, Wallace, Michael B , Pleskow, Douglas , Leggett, Cadman L , Trindade, Arvind J.

Mayo Clinic

Endoscopy | June 25, 2020 | Volume: 53 | Issue: 03 | Pages: 218-225

10.1055/a-1194-0397 | PMID 32515006 Get It

Abstract Background Volumetric laser endomicroscopy (VLE) allows for near-microscopic imaging of the superficial esophageal wall and may improve detection of early neoplasia in Barrett’s esophagus (BE). Interpretation of a 6-cm long, circumferential VLE “full scan” may however be challenging for endoscopists. We aimed to evaluate the accuracy of VLE experts in correctly diagnosing VLE full scans of early neoplasia and non-dysplastic BE (NDBE). Methods 29 VLE full scan videos (15 neoplastic and 14 NDBE) were randomly evaluated by 12 VLE experts using a web-based module. Experts were blinded to the endoscopic BE images and histology. The 15 neoplastic cases contained a subtle endoscopically visible lesion, which on endoscopic resection showed high grade dysplasia or cancer. NDBE cases had no visible lesions and an absence of dysplasia in all biopsies. VLE videos were first scored as “neoplastic” or “NDBE.” If neoplastic, assessors located the area most suspicious for neoplasia. Primary outcome was the performance of VLE experts in differentiating between non-dysplastic and neoplastic full scan videos, calculated by accuracy, sensitivity, and specificity. Secondary outcomes included correct location of neoplasia, interobserver agreement, and level of confidence. Results VLE experts correctly labelled 73 % (95 % confidence interval [CI] 67 % – 79 %) of neoplastic VLE videos. In 54 % (range 27 % – 66 %) both neoplastic diagnosis and lesion location were correct. NDBE videos were consistent with endoscopic biopsies in 52 % (95 %CI 46 % – 57 %). Interobserver agreement was fair (kappa 0.28). High level of confidence was associated with a higher rate of correct neoplastic diagnosis (81 %) and lesion location (73 %). Conclusions Identification of subtle neoplastic lesions in VLE full scans by experts was disappointing. Future studies should focus on improving methodologies for reviewing full scans, development of refined VLE criteria for neoplasia, and computer-aided diagnosis of VLE scans.
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas
Boxerman, Jerrold L. , Quarles, C. Chad , Hu, Leland , Gerstner, Elizabeth R. , Smits, Marion , Barboriak, Daniel P. , Huang, Raymond, Wick, Wolfgang , Weller, Michael , Kalpathy–Cramer, Jayashree , Shankar, Lalitha , Jacobs, Paula , Chung, Caroline , Bent, Martin J. van den , Chang, Susan M. , Yung, Wai Kuen, Wen, Patrick Y. , Rosen, Bruce R. , Arons, David F., Kingston, Ann E, Sandak, David, Wallace, M. Z., Musella, Al , Haynes, Chas, Weller, Michael , van den Bent, Martin J , Boxerman, Jerrold L , Wick, Wolfgang , Smits, Marion , Barboriak, Daniel P , Erickson, Bradley J. , Kaufmann, Timothy J. , Galanis, Evanthia , Chang, Susan Marina , Yung, W K Al, Cloughesy, Timothy F. , Wen, Patrick Yung , Gilbert, Mark R. , Ellingson, Benjamin M. , Schmainda, Kathleen M

Mayo Clinic

Neuro-Oncology | June 3, 2020 | Volume: 22 | Issue: 9 | Pages: 1262-1275

10.1093/neuonc/noaa141 | PMID 32516388 Get It

Abstract Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated consensus DSC-MRI protocol compatible with the standardized brain tumor imaging protocol (BTIP) for high-grade gliomas that is increasingly used in the clinical setting and is the default MRI protocol for the National Clinical Trials Network. After reviewing the basis for controversy over DSC-MRI protocols, this paper provides evidence-based best practices for clinical DSC-MRI as determined by the Committee, including pulse sequence (gradient echo vs spin echo), BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) FA and field strength-dependent TE (40–50 ms at 1.5 T, 20–35 ms at 3 T) provides overall best accuracy and precision for cerebral blood volume estimates. When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-dependent TE provides excellent performance, with reduced contrast agent usage and elimination of potential systematic errors introduced by variations in preload dose and incubation time.
Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.
Groen, Harry J.M. , Akerley, Wallace , Souquet, Pierre Jean , Laack, Eckart, Wolf, Juergen, Tan, Daniel Shao-Weng , Heist, Rebecca S. , Waldron-Lynch, Maeve, Mouhaër, Sylvie Le, Nwana, Ngozi, Giovannini, Monica, Han, Ji-Youn , Smit, Egbert F , Mansfield, Aaron S. , Garon, Edward B. , Orlov, Sergey

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 9520-9520

10.1200/jco.2020.38.15_suppl.9520 Get It

9520 Background: Capmatinib (INC280) has shown promising efficacy in patients (pts) with MET exon 14 ( METex14)–mutated NSCLC who were pretreated (cohort 4) or treatment (tx)-naïve (cohort 5b) in the ongoing, multicohort, phase 2 GEOMETRY mono-1 study. We report the results for pts enrolled in the expansion cohort 6 with either high-level MET amplification (gene copy number [GCN] ≥10) or METex14 mutation (any MET GCN) whose disease progressed on 1 prior line of systemic therapy. Methods: Adult pts (≥18 years), ECOG PS 0–1 who had ALK and EGFR wt, stage IIIB/IV NSCLC (any histology) received capmatinib tablets 400 mg twice daily (with or without food). Key efficacy endpoints were overall response rate (ORR) and duration of response (DOR) by blinded independent review committee (BIRC) per RECIST v1.1. Other secondary endpoints included investigator-assessed ORR, DOR, disease control rate (DCR), progression-free survival (PFS; BIRC and investigator assessment) and safety. Results: As of Jan 6, 2020, 34 NSCLC pts with METex14 mutation (n = 31) or high-level MET amplification (n = 3) were included in this analysis. Tx was ongoing for 38.2% of pts. In METex14-mutated NSCLC pts, per BIRC assessment: ORR was 48.4%, median DOR was 6.93 months (mo, not yet mature, 95% CI: 4.17–NE) and median PFS was 8.11 mo (not yet mature, 95% CI: 4.17–9.86). Investigator-assessed responses were similar to BIRC assessment (Table). Only 3 pts with high-level MET amplification were included in this cohort due to challenges in enrollment. All 3 pts had stable disease per BIRC assessment and were on treatment for 48, 85 and 97 days. Most common AEs (≥25%, all grades, N = 34) were peripheral edema (64.7%), nausea (35.3%), fatigue (29.4%), back pain (26.5%) and vomiting (26.5%). Data for pts with brain metastasis will be presented at the ASCO 2020 meeting. Conclusions: Capmatinib was confirmed to be efficacious in 2nd line, METex14-mutated NSCLC pts. This is the first cohort where capmatinib has been administered without fasting restriction and data confirm the favorable safety profile. Clinical trial information: NCT02414139 . [Table: see text]
MISS RATE DUE TO FAILURE RECOGNITION: ARTIFICIAL INTELLIGENCE ESTIMATE BASED ON A HIGH-QUALITY. A RANDOMIZED CLINICAL TRIAL
Badalamenti, Matteo , Lamonaca, Laura , Alkandari, Asma , Galtieri, PA, Leo, MD, Hassan, Cesare , Sharma, Prateek , Wallace, Michael B. , Rösch, Thomas , Maselli, Roberta , Spadaccini, Marco , Bhandari, Pradeep , Fugazza, Alessandro , Pellegatta, Gaia , Capogreco, Antonio , Carrara, Silvia , Anderloni, Andrea , Repici, Alessandro

Mayo Clinic

Endoscopy | May 11, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1704080 Get It

REAL-TIME COMPUTER AIDED DETECTION OF COLORECTAL NEOPLASIA AT COLONOSCOPY ACCORDING TO THE INDICATION: A RANDOMIZED CLINICAL TRIAL
Badalamenti, Matteo , Randonotti, E, Ferrara, E., Lamonaca, Laura , Alkandari, Asma , Andrealli, Alida, Repici, Alessandro , Maselli, Roberta , Radaelli, Franco , Pellegatta, Gaia , Galtieri, P.A. , Anderloni, Andrea , Carrara, Silvia , Craviotto, Vincenzo , Spadaccini, Marco , Capogreco, Antonio , Rösch, Thomas , Wallace, Michael B. , Sharma, Prateek , Hassan, Cesare

Mayo Clinic

Endoscopy | May 11, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1704035 Get It

Consensus practice guidelines on interventions for lumbar facet joint pain from a multispecialty, international working group
Cohen, Steven P. , Bhaskar, Arun , Buvanendran, Asokumar , Garg, Shuchita , Hooten, W. Michael , Hurley, Robert W. , Kennedy, David J. , McLean, Brian, Pangarkar, Sanjog , Provenzano, David A., Rauck, Richard, Sitzman, B. Todd, Smuck, Matthew , Zundert, Jan Van , Vorenkamp, Kevin E. , Wallace, Mark S. , Zhao, Zirong , Hooten, W Michael , van Zundert, Jan , Cohen, Steven P , Hurley, Robert W , Bhatia, Anuj , Deer, Timothy R. , Moon, Jee Youn , Narouze, Samer

Mayo Clinic

Regional Anesthesia & Pain Medicine | April 3, 2020 | Volume: 45 | Issue: 6 | Pages: 424-467

10.1136/rapm-2019-101243 | PMID 32245841 Get It

Background The past two decades have witnessed a surge in the use of lumbar facet blocks and radiofrequency ablation (RFA) to treat low back pain (LBP), yet nearly all aspects of the procedures remain controversial. Methods After approval by the Board of Directors of the American Society of Regional Anesthesia and Pain Medicine, letters were sent to a dozen pain societies, as well as representatives from the US Departments of Veterans Affairs and Defense. A steering committee was convened to select preliminary questions, which were revised by the full committee. Questions were assigned to 4–5 person modules, who worked with the Subcommittee Lead and Committee Chair on preliminary versions, which were sent to the full committee. We used a modified Delphi method, whereby the questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chair, who incorporated the comments and sent out revised versions until consensus was reached. Results 17 questions were selected for guideline development, with 100% consensus achieved by committee members on all topics. All societies except for one approved every recommendation, with one society dissenting on two questions (number of blocks and cut-off for a positive block before RFA), but approving the document. Specific questions that were addressed included the value of history and physical examination in selecting patients for blocks, the value of imaging in patient selection, whether conservative treatment should be used before injections, whether imaging is necessary for block performance, the diagnostic and prognostic value of medial branch blocks (MBB) and intra-articular (IA) injections, the effects of sedation and injectate volume on validity, whether facet blocks have therapeutic value, what the ideal cut-off value is for a prognostic block, how many blocks should be performed before RFA, how electrodes should be oriented, the evidence for larger lesions, whether stimulation should be used before RFA, ways to mitigate complications, if different standards should be applied to clinical practice and clinical trials and the evidence for repeating RFA (see table 12 for summary). Conclusions Lumbar medial branch RFA may provide benefit to well-selected individuals, with MBB being more predictive than IA injections. More stringent selection criteria are likely to improve denervation outcomes, but at the expense of more false-negatives. Clinical trials should be tailored based on objectives, and selection criteria for some may be more stringent than what is ideal in clinical practice.